Page 2

2

Attachment II details the key assumptions and financial information behind the growth percentages presented in Attachment I. Attachment III presents responses to Part C payment-related comments on the CY 2026 Advance Notice. Attachment IV presents responses to Part D payment-related comments on the CY 2026 Advance Notice. Attachment V provides the final Part D benefit parameters and details how they are updated. Attachment VI presents responses to comments on updates for MA and Part D Star Ratings. Attachment VII contains economic information for significant provisions in the CY 2026 Rate Announcement. Attachment VIII contains the RxHCC model risk adjustment factors and predictive ratio tables. Key Updates from the CY 2026 Advance Notice Growth Percentages: Attachment I provides the final estimates of the National Per Capita MA Growth Percentage and the FFS Growth Percentage, upon which the capitation rates are based, and information on deductibles for Medical Savings Accounts. Each year for the Rate Announcement, CMS updates the growth rates to be based on the most current estimate of per capita costs, based on the available historical program experience and projected trend assumptions at that time. The growth rates change between proposed and final as CMS incorporates updated data and assumptions. This year, the change in growth rates from the Advance Notice to the Rate Announcement is due primarily to incorporation of additional payment data, including through the fourth quarter of 2024. Calculation of FFS Cost: Episode savings / losses for two of the Innovation Center models listed in the CY 2026 Advance Notice Table II-5 are not available for CY 2023 and, therefore, will not be represented in the calculation of the CY 2026 non-End Stage Renal Disease (ESRD) MA ratebooks. The two affected models are the Oncology Care Model and the Enhancing Oncology Model. Policies Adopted as Described As in past years, policies in the Advance Notice that are not modified or retracted in the Rate Announcement become effective for the upcoming payment year. Clarifications in this CY 2026 Rate Announcement supersede information in the Advance Notice and prior Rate Announcements. Technical Update to Medical Education Payments in the Non-ESRD USPCC Baseline: We are finalizing the completion of the three-year phase-in schedule as proposed in the CY 2026